[A25-37] Delgocitinib (moderate to severe chronic hand eczema) – Addendum to Project A24-107
Last updated 03.04.2025
Project no.:
A25-37
Commission:
Commission awarded on 25.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Adult patients with moderate to severe chronic hand eczema for whom topical corticosteroids are inadequate or inappropriate
unchanged after addendum:
Added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-37
| Project no. | Title | Status |
|---|---|---|
| A24-107 | Delgocitinib (moderate to severe chronic hand eczema) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-04-03 A G-BA decision was published.